Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Everolimus, sold under the brand name Afinitor among others, is a medication used as an immunosuppressant to prevent rejection of organ transplants and as a targeted therapy in the treatment of renal cell cancer and other tumours.
Read the full article on WikipediaMetastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET) Clinical criteria: Treatment Phase: Continuing treatment Patient must have previously been issued with an authority prescription for this drug, AND Patient must not have disease progression, AND The treatment must be as monotherapy. Patients who have progressive disease with this drug are no longer eligible for PBS-subsidised treatment with this drug.
Stage IV clear cell variant renal cell carcinoma (RCC) Clinical criteria: Treatment Phase: Initial treatment Patient must have progressive disease according to the Response Evaluation Criteria in Solid Tumours (RECIST) following prior treatment with a tyrosine kinase inhibitor, AND Patient must have a WHO performance status of 2 or less, AND The treatment must be the sole PBS-subsidised therapy for this condition. Patients who have developed intolerance to a tyrosine kinase inhibitor of a severity necessitating permanent treatment withdrawal are eligible to receive PBS-subsidised everolimus. Patients who have progressive disease with everolimus are no longer eligible for PBS-subsidised everolimus.
Tuberous sclerosis complex (TSC) Clinical criteria: Treatment Phase: Continuing treatment The condition must be subependymal giant cell astrocytomas (SEGAs) associated with TSC; OR The condition must be visceral tumours associated with TSC, AND The treatment must be the sole PBS-subsidised therapy for this condition, AND Patient must have received an initial authority prescription for this drug for this condition, AND Patient must have demonstrated a response to prior treatment.
Refractory seizures associated with tuberous sclerosis complex Clinical criteria: Treatment Phase: Initial treatment Patient must have a confirmed diagnosis of tuberous sclerosis complex (TSC), AND Patient must be experiencing a minimum of two partial-onset seizures per week, AND The condition must have failed to be controlled satisfactorily at stable doses of at least two antiseizure medications, AND The treatment must be in combination with at least one antiseizure medication, AND Patient must not be a candidate for curative surgery. Population criteria: Patient must be at least 2 years of age.
Metastatic (Stage IV) breast cancer Clinical criteria: The condition must be hormone receptor positive, AND The condition must be human epidermal growth factor receptor 2 (HER2) negative, AND The condition must have acquired endocrine resistance as demonstrated by initial response and then recurrence or progression of disease after treatment with letrozole or anastrozole, AND The treatment must be in combination with exemestane. Population criteria: Patient must not be pre-menopausal.
Management of renal allograft rejection Clinical criteria: Treatment Phase: Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of renal allograft rejection, AND The treatment must be under the supervision and direction of a transplant unit.
Management of cardiac allograft rejection Clinical criteria: Treatment Phase: Management (initiation, stabilisation and review of therapy) Patient must be receiving this drug for prophylaxis of cardiac allograft rejection, AND The treatment must be under the supervision and direction of a transplant unit.
“Compared with the parent compound rapamycin, everolimus is more water-soluble. Compared to rapamycin, everolimus is more selective for the mTORC1 protein complex, with little impact on the mTORC2 complex. This can lead to a hyper-activation of the kinase AKT via inhibition on the mTORC1 negative feedback loop, while not inhibiting the mTORC2 positive feedback to AKT. This AKT elevation can lead to longer survival in some cell types.[medical citation needed] Thus, everolimus has important effects on cell growth, cell proliferation and cell survival.”
“~30 hours”
Working under the parallel aged-care framework? Aged-care equivalent →